Difference between revisions of "Team:EPFL"
| Line 21: | Line 21: | ||
<p class="lead text-white">Cancer Personalized Encapsulin Immunotherapy and Relapse Assay</p> | <p class="lead text-white">Cancer Personalized Encapsulin Immunotherapy and Relapse Assay</p> | ||
<div class="mt-5"> | <div class="mt-5"> | ||
| − | <a href=" | + | <a href="https://2018.igem.org/Team:EPFL/Description" class="btn btn-white btn-circle btn-translate--hover btn-icon mr-sm-4 scroll-me"> |
<span class="btn-inner--text">Learn more about our project</span> | <span class="btn-inner--text">Learn more about our project</span> | ||
<span class="btn-inner--icon"><i class="fas fa-angle-right"></i></span> | <span class="btn-inner--icon"><i class="fas fa-angle-right"></i></span> | ||
Revision as of 10:04, 24 August 2018
CAPOEIRA
Cancer Personalized Encapsulin Immunotherapy and Relapse Assay
What is CAPOEIRA ?
While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can be divided into the following parts:
Detection
Detection of cancer patient specific tumor mutations and neoantigens
Vaccine
Expression of the neoantigens and the adjuvant using encapsulin
Immune response
Maturation of dendritic cells and T-cells
Follow up
Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA